NEU1 and metabolic dysfunction-associated steatohepatitis: Last, as these compounds appear to be effective in inhibiting membrane NEU-1 in vitro, they could be used in in vivo models to down-regulate this protein involved in several diseases such as atherosclerosis, thrombosis, insulin resistance, non-alcoholic steatohepatitis, and cancer.